• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides methods for administering an adenoviral gene transfer vector comprising an exogenous gene to an animal. One method involves utilizing systemic neutralizing antibodies to neutralize the adenoviral gene transfer vector outside a targeted muscle. Another method involves the repeat administration of an adenoviral gene transfer vector to a skeletal muscle.
    公开号:US20010006947A1
    申请号:US09/174,508
    申请日:1998-10-16
    公开日:2001-07-05
    发明作者:Joseph T. Bruder；Imre Kovesdi
    申请人:Genvec Inc；
    IPC主号:A61K48-00
    专利说明:
    [0001] The present invention relates to methods useful in the administration of gene products to animals using adenoviral vectors. [0001] BACKGROUND OF THE INVENTION
    [0002] Modified viruses have proven convenient vector systems for investigative and therapeutic gene transfer applications, and adenoviral vector systems present several advantages for such uses. Adenoviruses are generally associated with benign pathologies in humans, and the 36 kb of the adenoviral genome has been extensively studied. Adenoviral vectors can be produced in high titers (e.g., about 10[0002] 13 pfu), and such vectors can transfer genetic material to nonreplicating, as well as replicating, cells (in contrast with, for example, retroviral vectors which only transfer genetic material to replicating cells). The adenoviral genome can be manipulated to carry a large amount of exogenous DNA (up to about 8 kb), and the adenoviral capsid can potentiate the transfer of even longer sequences (Curiel et al., Hum. Gene Ther., 3, 147-154 (1992)). Additionally, adenoviruses generally do not integrate into the host cell chromosome, but rather are maintained as a linear episome, thus minimizing the likelihood that a recombinant adenovirus will interfere with normal cell function. Aside from being a superior vehicle for transferring genetic material to a wide variety of cell types, adenoviral vectors represent a safe choice for gene transfer, a particular concern for therapeutic applications.
    [0003] A variety of recombinant adenoviral vectors have been described. Most of the vectors in use today derive from the adenovirus serotype 5 (Ad5), a member of subgroup C. An exogenous gene of interest typically is inserted into the early region 1 (E1) of the adenovirus. Disruption of the E1 region decreases the amount of viral proteins produced by both the early regions (DNA binding protein) and late regions (penton, hexon, and fiber proteins), preventing viral propagation. These replication deficient adenoviral vectors require growth in either a complementary cell line or in the presence of an intact helper virus, which provides, in trans, the essential E1 functions (Berker et al., [0003] J. Virol., 61, 1213-1220 (1987); Davidson et al., J. Virol., 61, 1226-1239 (1987); Mansour et al., Mol. Cell Biol., 6, 2684-2694 (1986)). More recently, adenoviral vectors deficient in both E1 and the early region 4 (E4) have been used to substantially abolish expression of viral proteins. In order to insert the larger genes (up to 8 kb) into the adenoviral genome, adenoviral vectors additionally deficient in the nonessential early region 3 (E3) are used. Multiply deficient adenoviral vectors are described in published PCT patent application WO 95/34671.
    [0004] One limitation of adenoviral vector systems is the ability of the adenoviral vector to transduce a wide variety of proliferating and quiescent cells (Michou et al., [0004] Gene Ther., 4, 473-482 (1997)). This ability, while a benefit in transducing the target area, is a limitation when the adenoviral vector “leaks” out of the targeted area and transduces other cells it contacts. Tranduction of the surrounding cells is a severe problem when the gene product encoded by the adenoviral vector is harmful, toxic, or otherwise undesirable with respect to these non-targeted areas.
    [0005] Another limitation of the adenoviral vector system is the cellular and humoral immune response generated within the host animal. Initial administration elicits a reaction from both CD8[0005] + and CD4+ T cell lymphocytes which eliminate virus infected cells within 28 days after infection, limiting the duration of the transgene expression. In addition, neutralizing antibodies produced by B lymphocytes in cooperation with CD4+ cells inhibit the effectiveness of a repeat administration of the adenoviral vector. Proliferation and specificity of the antibodies is achieved through interactions between the adenoviral vector, B-cell surface immunoglobulins and activated CD4+ surface proteins (particularly CD40Li, which binds CD40 on the surface of the B cell) (Yang et al., J. Virol., 69, 2004 (1995)).
    [0006] Attempts to circumvent the humoral immune response to allow repeat administration of the adenoviral vector have met with limited success. These attempts have been focused in two areas, immunosuppression and alteration of the adenoviral vector. Several groups have experimented with various immunosuppressant drugs or antibodies specific for CD4[0006] +, CD40 ligand, or CTLA4Ig to reduce the adenovirus-specific humoral immune response (Lee et al., Hum. Gene Ther., 7, 2273 (1996) (CD4+); Yang et al., J. Virol., 70, 6370 (1996) (CD40 ligand); Kay et al., Nature Gen., 11, 191 (1995) (CTLA4Ig)). Although some of these results have been encouraging, there is a substantial risk associated with systemic immune suppression in a clinical setting.
    [0007] In another study, subretinal administration of an adenoviral vector containing the bacterial β-galactosidase gene resulted in minimal circulating antibodies specific to the adenoviral vector. This was most likely a reflection of the immune privileged status of the retina. Although there was minimal retinal toxicity to the adenovirus, several of the animals injected developed localized granulomatous infiltrate at the injection site (Bennett et al., [0007] Hum. Gene Ther., 7, 1763-1769 (1996)). Subretinal administration is not an option for many applications where adenoviral vectors are employed.
    [0008] Alteration of the adenoviral vector is time consuming and has not been entirely successful in sufficiently attenuating the immune response. Limited readministration of the adenoviral vector has been accomplished when adenoviral vectors of different serotypes within the same subgroup are used; however, persistence of expression of the transgene was not comparable to the initial administration (Mack et al., [0008] Hum. Gene Ther., 8, 99-109 (1997)).
    [0009] Accordingly, there is a need for improved methods of administering adenoviral vectors to animals, particularly, to prevent leakage of the adenoviral vector from the target area and to circumvent the humoral immune response elicited by adenoviral vectors. The present invention provides such methods. This and other advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein. [0009] BRIEF SUMMARY OF THE INVENTION
    [0010] The present invention provides a method of targeting a gene product in a particular muscle of an animal. The method utilizes systemic neutralizing antibodies to neutralize an adenoviral gene transfer vector containing an exogenous gene outside the particular muscle. The adenoviral gene transfer vector is administered such that the exogenous gene is expressed and the gene product is produced only in the particular muscle of administration. [0010]
    [0011] The present invention further provides a method of producing a gene product in a skeletal muscle of an animal. The method comprises a first intramuscular administration of an adenoviral vector to the skeletal muscle of an animal, and a second administration of an adenoviral gene transfer vector containing an exogenous gene encoding a gene product. Administration is such that the exogenous gene is expressed and the gene product is produced in the skeletal muscle of the animal. [0011]
    [0012] The invention may best be understood with reference to the accompanying drawings and in the following detailed description. [0012] BRIEF DESCRIPTION OF THE DRAWINGS
    [0013] FIG. 1 is a schematic diagram depicting the original adenovirus used to derive the adenoviral vectors AdCMVNull and AdCMV.Z, the regions of addition and deletion of the original adenovirus, and the expression cassettes of the adenoviral vectors AdCMVNull and AdCMV.Z. [0013] DETAILED DESCRIPTION OF THE INVENTION
    [0014] The present invention provides methods useful in the administration of gene products to animals using adenoviral gene transfer vectors. The ability to target an adenoviral vector and to repeatedly administer a therapeutic adenoviral vector in a clinical setting is useful in improving treatment efficacy and in enabling the treatment of diseases. This invention provides a method to limit the infection of non-target tissue following administration of an adenoviral vector to a particular muscle of an animal. The vector targeting potential is useful for cardiac, particularly, endocardial, administration, as the risk of misinjection of the adenoviral vector is high. As adenoviral vectors cannot be readministered systemically, the present invention also provides a method for repeat administration of an adenoviral gene transfer vector comprising an exogenous gene to the skeletal muscle of an animal. [0014]
    [0015] The term “exogenous gene”, as it is used herein, refers to any gene in an adenoviral gene transfer vector which is not native to the adenovirus which comprises the adenoviral vector. The gene includes a nucleic acid sequence encoding a gene product operably linked to a promoter. Any portion of the gene can be non-native to the adenovirus which comprises the adenoviral vector. For example, the gene can comprise a non-native nucleic acid sequence encoding a gene product which is operably linked to a native promoter. It should be appreciated that the exogenous gene can be any gene encoding an RNA or protein of interest to the skilled artisan. Therapeutic genes, genes encoding a protein that is to be studied in vitro and/or in vivo, genes encoding anti-sense RNA's, and modified viral genes are illustrative of possible exogenous genes. [0015]
    [0016] The term “adenoviral gene transfer vector”, as it is used herein, refers to any replication incompetent adenoviral vector with an exogenous gene encoding a gene product inserted into its genome. The vector must be capable of replicating and being packaged when any deficient essential genes are provided in trans. An adenoviral vector desirably contains at least a portion of each terminal repeat required to support the replication of the viral DNA, preferably at least about 90% of the full ITR sequence, and the DNA required to encapsidate the genome into a viral capsid. Many suitable adenoviral vectors have been described in the art. [0016]
    [0017] In one embodiment, the present invention provides a method of targeting a gene product to a muscle of an animal using an adenoviral gene transfer vector containing an exogenous gene encoding a gene product. Systemic neutralizing antibodies to a particular adenoviral gene transfer vector are first induced in the animal. The adenoviral vector is then administered to a particular muscle of an animal such that the exogenous gene encoded by the adenoviral vector is expressed and the gene product produced in the particular muscle of the animal. In addition, the adenoviral vector is neutralized outside the muscle of administration. [0017]
    [0018] The present invention can be practiced with any suitable animal, preferably a mammal, more preferably, a human. Additionally, the adenoviral vector can be administered to any suitable muscle of the animal; however, it is preferably administered to the heart. [0018]
    [0019] Any suitable method can be used to induce systemic neutralizing antibodies to the adenoviral vector. Desirably, an antigen is administered to the animal. This antigen can be the adenoviral gene transfer vector, but preferably, it is an identical adenoviral vector, except without an exogenous gene (an AdCMVNull vector, an example of which can be found in FIG. 1). The antigen can also be administered by any suitable method. Depending on the antigen, administration can be to any suitable area of the animal. In order to induce the systemic neutralizing antibodies, the antigen can be administered any number of suitable times, e.g., once, twice, or more. [0019]
    [0020] Using the AdCMVNull vector administration, the antigen can be administered systemically (rather than to the target muscle) to prevent any damage to the particular muscle. Systemic administration can be accomplished through intravenous injection, either bolus or continuous, or any other suitable method. An added benefit of systemic administration is that it requires a much smaller amount of antigen to produce the same levels of circulating antibodies as administration to any muscle of the animal. [0020]
    [0021] Administration of the antigen produces circulating neutralizing antibodies. While not wishing to be bound by any particular theory, it is believed that when the adenoviral gene transfer vector is administered to the particular muscle of the animal, some of the adenoviral particles escape the muscle. These adenoviral particles are then neutralized by the antibodies circulating throughout the animal such that significantly less (and preferably substantially no) gene product is produced outside the particular muscle. The amount of exogenous gene product produced outside the area of administration is preferably at least 10% less (more preferably at least 50% less, and most preferably at least 80% less) than production of the gene product outside the particular muscle of administration in a naive animal, which does not have circulating neutralizing antibodies to the adenoviral gene transfer vector. [0021]
    [0022] Neutralization of adenoviral particles outside of the particular muscle prevents production of the exogenous gene carried in the adenoviral gene transfer vector. This is extremely useful in situations where the exogenous gene is harmful, or toxic, to the animal when present in areas other than the particular muscle of administration. An example of this is vascular endothelial growth factor (VEGF protein), which mediates vascular growth. While vascular growth is desirable in the heart to repair damaged cardiac muscle, growth outside the heart can lead to severe problems, including blindness, and increased aggressiveness of tumor cells. [0022]
    [0023] In another embodiment, the present invention provides a method of producing a gene product in a skeletal muscle. An adenoviral vector is first administered to the skeletal muscle of an animal. An adenoviral vector containing an exogenous gene encoding a gene product is then administered to the same skeletal muscle such that the exogenous gene is expressed and the gene product is produced in the skeletal muscle. Any suitable animal can be used; however, preferably, the animal is a mammal, more preferably, a human. [0023]
    [0024] After the second or subsequent administration of the adenoviral gene transfer vector, production of the gene product in the muscle of the animal is desirably at least 1% of (such as at least 10% of, preferably at least 50% of, more preferably at least 80% of, and most preferably, substantially the same as) production of the gene product after a first or preceding administration with the same adenoviral gene transfer vector containing the exogenous gene encoding the gene product. While not wishing to be bound by any particular theory, it is believed that the level of gene product produced in the skeletal muscle of an animal after the second or subsequent administration to the muscle can be substantially similar to that of the first or preceding administration because neutralizing antibodies, which are produced by the first or preceding administration, cannot readily penetrate the muscle and destroy the adenoviral gene transfer vector. This holds true even when the neutralizing antibody response is boosted with two or more initial administrations before the final or subsequent intramuscular administration of the adenoviral gene transfer vector containing the exogenous gene encoding the gene product. [0024]
    [0025] To facilitate the administration of adenoviral vectors, they can be formulated into suitable pharmaceutical compositions. Generally, such compositions include the active ingredient (i.e., the adenoviral vector) and a pharmacologically acceptable carrier. Such compositions can be suitable for delivery of the active ingredient to a patient for medical application, and can be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. [0025]
    [0026] Pharmaceutical compositions for use in accordance with the present invention can be formulated in a conventional manner using one or more pharmacologically or physiologically acceptable carriers comprising excipients, as well as optional auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Thus, for injection, the active ingredient can be formulated in aqueous solutions, preferably in physiologically compatible buffers. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art. For oral administration, the active ingredient can be combined with carriers suitable for inclusion into tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. For administration by inhalation, the active ingredient is conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant. The active ingredient can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Such compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Other pharmacological excipients are known in the art. [0026]
    [0027] The present inventive methods are useful in the context of the treatment of animals, e.g., medical treatment. In addition, the present inventive methods are useful in the production of gene products, e.g., in vivo protein production (which can entail subsequent protein recovery) as well as in research, e.g., investigation of gene expression, adenoviral targeting, and the like. [0027] EXAMPLE
    [0028] The present invention is further described in the following example. This example serves only to illustrate the invention and is not intended to limit the scope of the invention in any way. [0028]
    [0029] This example illustrates use of the present inventive method of targeting production of a gene product to a particular muscle in an animal, as well as the present inventive method of repeat administration to produce a gene product in a skeletal muscle of an animal. In particular, systemic neutralizing antibodies to an adenoviral vector were induced in an animal, and then the adenoviral vector comprising an exogenous gene encoding a gene product was administered to a particular muscle of the animal such that the exogenous gene was expressed and the gene product was produced in the particular muscle of the animal. In addition, the adenoviral vector was neutralized outside of the particular muscle of the animal such that there was limited expression of the exogenous gene resulting in production of the gene product outside of the particular muscle of the animal. [0029]
    [0030] For the purposes of this experimental work, C57B16 mice were used as the test animals because their immune system is able to recognize adenoviral vectors as foreign antigens and mount a sufficient immune response to destroy the adenoviral vectors, thereby preventing expression of an exogenous gene forming a part of the adenoviral vector. The mice were separated into three groups. Systemic neutralizing antibodies were induced in the mice of group 1 with an adenoviral vector which did not contain an exogenous gene encoding a gene product (AdCMVNull). A similar adenoviral vector (AdCMV.Z), with a gene expression cassette encoding a reporter gene product (i.e., a gene product that could be readily detected), was administered to the mice of groups 1 and 2 to determine whether production of the reporter gene product β-galactosidase (β-gal) was limited to the right gastrocnemius muscle or could be detected in other areas of the mice, particularly the liver inasmuch as adenoviral vectors are known to localize in the liver after entering the bloodstream of an animal (Jaffee et al., [0030] Nat. Genet., 1, 372-78 (1992)). The mice of group 2 were treated as a naive group. Only the adenoviral vector AdCMV.Z, with a gene expression cassette encoding the reporter gene product β-gal, was administered intrajugularly to the mice of group 2, i.e., no adenoviral vector was administered to induce systemic neutralizing antibodies in the mice before the administration of the adenoviral vector AdCMV.Z. The mice of group 2 otherwise were treated in the same manner as the mice of group 1. Finally, a control group, group 3, which did not receive any administration of adenoviral vectors, was included.
    [0031] The AdCMVNull vector was a replication-deficient adenoviral vector with deletions in the E1 and E3 regions. An expression cassette was inserted in the E1-deleted region of the adenoviral vector that included an SV40 polyA sequence and a cytomegaloviral promoter (CMV). The AdCMVNull vector is depicted in FIG. 1. [0031]
    [0032] The AdCMV.Z vector was also a replication-deficient adenoviral vector similar to the AdCMVNull vector, except that the expression cassette included a nucleic acid sequence encoding the reporter gene product β-gal operably linked to the CMV promoter, from left to right, relative to the viral vector. The AdCMV.Z vector is also depicted in FIG. 1. [0032]
    [0033] The protocol for administration of the AdCMVNull and AdCMV.Z vectors to the mice of the two groups was as follows: the mice of group 1 were immunized with an intramuscular injection of 1×10[0033] 10 pu of AdCMVNull on day 1 of the experiment, and received a subsequent intramuscular injection of 1×1010 pu of AdCMV.Z on day 14. The mice of group 2 (the naive mice) received an injection of 1×1010 pu of AdCMV.Z on day 14. The mice of group 3 did not receive any injections.
    [0034] On day 15, the mice in all three groups were sacrificed. The β-gal activity in the mice was determined in the liver and right gastrocnemius muscle. Neutralizing antibody titers also were determined in the mice. The results of these analyzes are set forth below in Table 1. [0034] TABLE 1 β-galactosidase Neutralizing Activity (RLU/mg protein) AntibodiesRight Gastrocnemius (reciprocal Muscle Liver dilution)Group 1 1.4447 × 106 8.0697 × 103 32 (AdCMVNull) Group 2 4.0748 × 106 5.2022 × 106 1.0 (Naive) Group 3 1.0683 × 104  7.898 × 103 n/a (Control)
    [0035] As is apparent from the experimental results set forth above, the mice in the first two groups had essentially the same levels of β-gal activity in the right gastrocnemius muscle, about 10[0035] 6 RLU/mg. The mice of group 3 (the control group) had a β-gal activity level of about 104 RLU/mg. The results demonstrate that there was gene expression in the targeted muscle, even in the mice of group 1, which were the subject of the repeat administration. Moreover, the mice of group 1, in which systemic neutralizing antibodies were induced, had significantly less β-gal activity in the liver, about 104 (or a hundred-fold less than measured in the target muscle and approximately the same as the control), thereby demonstrating that there was localization of the targeted gene product to the targeted muscle in accordance with the present invention. In distinct contrast, the mice of group 2, in which neutralizing antibodies were not induced, had essentially the same level of β-gal activity in the liver, about 106 RLU/mg, as in the targeted muscle, thereby indicating that in the absence of the present inventive method, when there is undesirable leaking of the adenoviral vector outside the targeted muscle, there is wide-spread production of the gene product of interest.
    [0036] All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference. [0036]
    [0037] While this invention has been described with an emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the invention as defined by the claims below. [0037]
    权利要求:
    Claims (19)
    [1" id="US-20010006947-A1-CLM-00001] 1. A method of targeting a gene product to a particular muscle of an animal, said method comprising (a) inducing in an animal systemic neutralizing antibodies to an adenoviral gene transfer vector, (b) administering said adenoviral gene transfer vector comprising an exogenous gene encoding a gene product to a particular muscle of said animal such that said exogenous gene is expressed and said gene product is produced in said particular muscle of said animal, and (c) neutralizing said adenoviral gene transfer vector outside of said particular muscle of said animal.
    [2" id="US-20010006947-A1-CLM-00002] 2. The method of
    claim 1 , wherein said animal is a mammal.
    [3" id="US-20010006947-A1-CLM-00003] 3. The method of
    claim 2 , wherein said mammal is a human.
    [4" id="US-20010006947-A1-CLM-00004] 4. The method of
    claim 1 , wherein said systemic neutralizing antibodies to said adenoviral gene transfer vector are produced by administration of an antigen.
    [5" id="US-20010006947-A1-CLM-00005] 5. The method of
    claim 4 , wherein said antigen is the same as said adenoviral gene transfer vector, except that it does not contain an exogenous gene encoding a gene product.
    [6" id="US-20010006947-A1-CLM-00006] 6. The method of
    claim 4 , wherein said antigen is the same as said adenoviral gene transfer vector.
    [7" id="US-20010006947-A1-CLM-00007] 7. The method of
    claim 4 , wherein said antigen is administered to said animal systemically.
    [8" id="US-20010006947-A1-CLM-00008] 8. The method of
    claim 1 , wherein said neutralizing of said adenoviral gene transfer vector outside said particular muscle of said animal is a result of the presence of said neutralizing antibodies.
    [9" id="US-20010006947-A1-CLM-00009] 9. The method of
    claim 1 , wherein said neutralizing of said adenoviral gene transfer vector outside said particular muscle of said animal is such that said production of said gene product is at least 90% less than the production of said gene product outside said particular muscle of a naive animal of the same species as said animal after administration of said adenoviral gene transfer vector.
    [10" id="US-20010006947-A1-CLM-00010] 10. The method of
    claim 9 , wherein said neutralizing of said adenoviral gene transfer vector outside said particular muscle of said animal is such that said production of said gene product is at least 99% less than the production of said gene product outside said particular muscle of a naive animal of the same species as said animal after administration of said adenoviral gene transfer vector.
    [11" id="US-20010006947-A1-CLM-00011] 11. The method of
    claim 10 , wherein said neutralizing of said adenoviral gene transfer vector outside said particular muscle of said animal is such that said production of said gene product is at least 99.9% less than the production of said gene product outside said particular muscle of a naive animal of the same species as said animal after administration of said adenoviral gene transfer vector.
    [12" id="US-20010006947-A1-CLM-00012] 12. A method of producing a gene product in a skeletal muscle of an animal, said method comprising (a) administering an adenoviral vector to said skeletal muscle of said animal, and (b) at least seven days after said administration, administering an adenoviral gene transfer vector comprising an exogenous gene encoding a gene product to said skeletal muscle of said animal such that said exogenous gene is expressed and said gene product is produced in said skeletal muscle of said animal.
    [13" id="US-20010006947-A1-CLM-00013] 13. The method of
    claim 12 , wherein said animal is a mammal.
    [14" id="US-20010006947-A1-CLM-00014] 14. The method of
    claim 13 , wherein said mammal is a human.
    [15" id="US-20010006947-A1-CLM-00015] 15. The method of
    claim 12 , wherein said adenoviral vector in step (a) is said adenoviral gene transfer vector comprising an exogenous gene encoding a gene product in step (b).
    [16" id="US-20010006947-A1-CLM-00016] 16. The method of
    claim 15 , wherein production of said gene product in said skeletal muscle of said animal as a result of said second intramuscular administration of said adenoviral gene transfer vector is at least 10% of the production of said gene product as a result of said first intramuscular administration of said adenoviral gene transfer vector comprising an exogenous gene encoding a gene product.
    [17" id="US-20010006947-A1-CLM-00017] 17. The method of
    claim 16 , wherein production of said gene product in said skeletal muscle of said animal as a result of said second intramuscular administration of said adenoviral gene transfer vector is at least 50% of the production of said gene product as a result of said first intramuscular administration of said adenoviral gene transfer vector comprising an exogenous gene encoding a gene product.
    [18" id="US-20010006947-A1-CLM-00018] 18. The method of
    claim 17 , wherein production of said gene product in said skeletal muscle of said animal as a result of said second intramuscular administration of said adenoviral gene transfer vector is at least 80% of the production of said gene product as a result of said first intramuscular administration of said adenoviral gene transfer vector comprising an exogenous gene encoding a gene product.
    [19" id="US-20010006947-A1-CLM-00019] 19. The method of
    claim 18 , wherein production of said gene product in said skeletal muscle of said animal as a result of said second intramuscular administration of said adenoviral gene transfer vector is at least substantially the same as the production of said gene product as a result of said first intramuscular administration of said adenoviral gene transfer vector comprising an exogenous gene encoding a gene product.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6440944B2|2002-08-27|Methods of administering adenoviral vectors
    Manthorpe et al.1993|Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice
    Hartikka et al.1996|An improved plasmid DNA expression vector for direct injection into skeletal muscle
    US5872154A|1999-02-16|Method of reducing an immune response to a recombinant adenovirus
    Braun2008|Muscular gene transfer using nonviral vectors
    Ferry et al.1998|Liver-directed gene transfer vectors
    Nishikawa et al.2002|Nonviral approaches satisfying various requirements for effective in vivo gene therapy
    Manoj et al.2004|Approaches to enhance the efficacy of DNA vaccines
    JP2003528024A|2003-09-24|Needle-free injection of formulated nucleic acid molecules
    JP2004331668A|2004-11-25|Medicine, composition and system for administration of naked polynucleotide which encodes biologically active peptide
    EP1015035B1|2009-01-28|Vaccination by topical application of genetic vectors
    Kaplan et al.1997|Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung
    JPH10507758A|1998-07-28|Gene therapy with simultaneous administration of adenovirus and immunosuppressive drugs
    Nabel et al.1993|Direct gene transfer for immunotherapy and immunization
    WO2001065911A9|2005-11-17|Improved poloxamer and poloxamine compositions for nucleic acid delivery
    Kaur et al.2020|Modified mRNA as a Therapeutic Tool for the Heart
    EP0930896B1|2003-01-02|Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
    Boulikas1998|Status of gene therapy in 1997: molecular mechanisms, disease targets, and clinical applications
    JP2004505113A|2004-02-19|Composition using herpes simplex virus glycoprotein D and method for suppressing immune response using the same
    US20020086837A1|2002-07-04|Acne vaccine
    AU743335B2|2002-01-24|Non-invasive administration of adeno-associated viral vectors
    US20120258540A1|2012-10-11|Methods for modifying virus surfaces
    Mumper et al.2000|Controlled plasmid delivery and gene expression
    Najjar et al.2014|DNA plasmids for non-viral gene therapy of cancer
    Lobo et al.1998|The 1st Annual Meeting of the American Society of Gene Therapy
    同族专利:
    公开号 | 公开日
    JP2002527483A|2002-08-27|
    WO2000023088A2|2000-04-27|
    EP1121136A2|2001-08-08|
    US6596270B2|2003-07-22|
    US20020013286A1|2002-01-31|
    US6440944B2|2002-08-27|
    CA2347083A1|2000-04-27|
    AU6432199A|2000-05-08|
    WO2000023088A3|2000-10-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20040052773A1|2002-01-18|2004-03-18|Inovio As|Production of multi-chain protein from muscle|
    US20060041219A1|1997-04-03|2006-02-23|Iacob Mathiesen|Method for muscle delivery of drugs, nucleic acids and other compounds|US5585362A|1989-08-22|1996-12-17|The Regents Of The University Of Michigan|Adenovirus vectors for gene therapy|
    EP1548118A2|1994-06-10|2005-06-29|Genvec, Inc.|Complementary adenoviral vector systems and cell lines|
    AT452981T|1995-06-07|2010-01-15|Univ North Carolina|TRANSDUCTION OF MOBILS BY VENEERS OF ADENOASSOZED VIRUSES|
    AUPN477695A0|1995-08-14|1995-09-07|Commonwealth Scientific And Industrial Research Organisation|Gene therapy|
    US5830879A|1995-10-02|1998-11-03|St. Elizabeth's Medical Center Of Boston, Inc.|Treatment of vascular injury using vascular endothelial growth factor|
    US6403370B1|1997-02-10|2002-06-11|Genstar Therapeutics Corporation|Oncolytic/immunogenic complementary-adenoviral vector system|
    US5981275A|1997-04-14|1999-11-09|Genzyme Corporation|Transgene expression system for increased persistence|EP1191104A1|2000-09-26|2002-03-27|Introgene B.V.|Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine|
    US20030086903A1|2001-11-02|2003-05-08|Genvec, Inc.|Therapeutic regimen for treating cancer|
    BR0316158A|2002-11-12|2005-09-27|Albert B Deisseroth|Adenoviral vector vaccine|
    JP2007535304A|2003-11-24|2007-12-06|シドニーキンメルキャンサーセンター|Mucin antigen vaccine|
    US8828957B2|2003-12-11|2014-09-09|Microvax, Llc|Methods for generating immunity to antigen|
    EP1856255A4|2005-02-11|2010-01-27|Univ Southern California|Method of expressing proteins with disulfide bridges|
    US20060286074A1|2005-05-31|2006-12-21|Yucheng Tang|Methods for immunotherapy of cancer|
    US9533036B2|2005-11-07|2017-01-03|Microvax, Llc|Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein|
    EP1951297A2|2005-11-10|2008-08-06|GenVec, Inc.|Adenoviral vector-based foot-and-mouth disease vaccine|
    US8008256B2|2006-05-01|2011-08-30|University Of Southern California|Combination therapy for treatment of cancer|
    WO2010056901A2|2008-11-13|2010-05-20|University Of Southern California|Method of expressing proteins with disulfide bridges with enhanced yields and activity|
    JP6960396B2|2015-04-07|2021-11-05|ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン|Methods for Inducing Cell Division in End-Division Cells|
    法律状态:
    1998-11-19| AS| Assignment|Owner name: GENVEC, INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRUDER, JOSEPH T.;KOVESDI, IMRE;REEL/FRAME:009591/0151 Effective date: 19981106 |
    2002-08-08| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2006-02-03| FPAY| Fee payment|Year of fee payment: 4 |
    2010-02-25| FPAY| Fee payment|Year of fee payment: 8 |
    2014-02-26| FPAY| Fee payment|Year of fee payment: 12 |
    优先权:
    申请号 | 申请日 | 专利标题
    US09/174,508|US6440944B2|1998-10-16|1998-10-16|Methods of administering adenoviral vectors|US09/174,508| US6440944B2|1998-10-16|1998-10-16|Methods of administering adenoviral vectors|
    PCT/US1999/024133| WO2000023088A2|1998-10-16|1999-10-15|Methods of administering adenoviral vectors|
    CA002347083A| CA2347083A1|1998-10-16|1999-10-15|Methods of administering adenoviral vectors|
    JP2000576862A| JP2002527483A|1998-10-16|1999-10-15|Methods for administering adenovirus vectors|
    AU64321/99A| AU6432199A|1998-10-16|1999-10-15|Methods of administering adenoviral vectors|
    EP99952011A| EP1121136A2|1998-10-16|1999-10-15|Methods of administering adenoviral vectors|
    US09/835,683| US6596270B2|1998-10-16|2001-04-16|Methods of administering adenoviral vectors|
    [返回顶部]